| MYCOF Stock | | | USD 0.01 0 28.57% |
Insider
Sanford Stein is Gen Officer of Mydecine Innovations Group
| Phone | 720 277 9879 |
| Web | https://www.mydecine.com |
Mydecine Innovations Management Efficiency
The company has return on total asset
(ROA) of
(1.7615) % which means that it has lost $1.7615 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(12.244) %, meaning that it generated substantial loss on money invested by shareholders. Mydecine Innovations' management efficiency ratios could be used to measure how well Mydecine Innovations manages its routine affairs as well as how well it operates its assets and liabilities.
Mydecine Innovations Group has accumulated 4.35
M in total debt with debt to equity ratio
(D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Mydecine Innovations has a current ratio of 1.23, suggesting that it
may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Mydecine Innovations until it has trouble settling it off, either with new capital or with free cash flow. So, Mydecine Innovations' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mydecine Innovations sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mydecine to invest in growth at high rates of return. When we think about Mydecine Innovations' use of debt, we should always consider it together with cash and equity.
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Mydecine Innovations operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 11 people. Mydecine Innovations Group [MYCOF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Mydecine Innovations Leadership Team
Elected by the shareholders, the Mydecine Innovations' board of directors comprises two types of representatives: Mydecine Innovations inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mydecine. The board's role is to monitor Mydecine Innovations' management team and ensure that shareholders' interests are well served. Mydecine Innovations' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mydecine Innovations' outside directors are responsible for providing unbiased perspectives on the board's policies.
Mydecine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Mydecine Innovations a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.